Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Nektar Therapeutics (NKTR) reported its financial results for Q4 and the full year 2020. Q4 revenue decreased to $23.5 million from $33.9 million in 2019, while annual revenue rose to $152.9 million, driven by $50 million in milestones from Bristol-Myers Squibb. Operating expenses totaled $134.2 million for Q4 and $578 million for the year, reflecting higher R&D costs despite a decrease in R&D expenses from 2019. The company reported a net loss of $117.2 million for Q4, and $444.4 million for the year. Nektar continues to advance its pipeline, notably with ongoing studies of bempegaldesleukin.
Nektar Therapeutics (NKTR) will announce its fourth quarter and annual financial results for 2020 on February 25, 2021, after U.S. markets close. A conference call hosted by President and CEO Howard Robin will begin at 5:00 p.m. ET. Investors can access the call via the company's website. Nektar specializes in biopharmaceuticals with a diverse portfolio in oncology, immunology, and virology. The results are highly anticipated as they will provide insights into the company's performance and future outlook.
Nektar Therapeutics (NASDAQ: NKTR) announced a collaboration with Merck for a Phase 2/3 clinical trial of bempegaldesleukin (BEMPEG) combined with KEYTRUDA® (pembrolizumab) in treating metastatic or unresectable recurrent squamous cell carcinoma of the head and neck. The study aims to enroll 500 patients and will assess overall response rate (ORR) and overall survival (OS). An interim analysis will be performed after 200 patients have been followed for at least four months. If successful, the trial will proceed to the Phase 3 stage.
Nektar Therapeutics (NKTR) announced a collaboration with SFJ Pharmaceuticals to advance the development of Bempegaldesleukin (BEMPEG) for treating head and neck cancer. SFJ will provide up to $150 million in funding for a Phase 2/3 clinical study involving BEMPEG and pembrolizumab in patients with PD-L1 expressing tumors. Nektar will sponsor the study and will make milestone payments to SFJ contingent on regulatory approvals. This partnership allows Nektar to expand its BEMPEG program without diluting shareholder equity, as highlighted by Howard Robin, President and CEO.
Nektar Therapeutics' President and CEO, Howard Robin, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on January 11, 2021, at 11:50 a.m. PT. This presentation will include a Q&A session accessible via a Webcast available on the Nektar Investor Events Calendar. Interested individuals can access the replay until February 10, 2021. Nektar, headquartered in San Francisco, focuses on developing investigational medicines in oncology, immunology, and virology, alongside a portfolio of approved partnered medicines.
Nektar Therapeutics (NASDAQ: NKTR) has appointed Brian Kotzin, MD, as Interim Chief Medical Officer and Head of Development, effective immediately. Dr. Kotzin, previously Senior Vice President of Clinical Development and Head of Immunology since 2017, will replace Wei Lin, who is leaving for another opportunity. Dr. Kotzin brings over 30 years of experience in immunology, having led significant development programs including NKTR-358. His leadership is expected to strengthen Nektar's focus on its immune-oncology and immunology pipeline.
Nektar Therapeutics has announced a deal to sell its royalties from ADYNOVATE and MOVANTIK to Healthcare Royalty Management for $150 million, expected by December 31, 2020. These funds will support clinical trials for Nektar's immune-oncology programs. The agreement allows HCR to receive royalties up to $210 million by 2025, reverting to Nektar after. By year-end 2020, Nektar anticipates holding about $1.2 billion in cash and investments. This non-dilutive financing aims to strengthen Nektar's financial position as it advances its IL-2 and IL-15 pipeline programs.
Nektar Therapeutics (NASDAQ:NKTR) announced the dosing of the first patient in a Phase 1/2 trial of NKTR-255, aimed at treating relapsed/refractory head and neck squamous cell carcinoma and colorectal cancer. The trial involves up to 80 patients across 15 sites in the U.S. and EU, assessing NKTR-255 alongside cetuximab. NKTR-255 activates the IL-15 pathway, promoting NK and CD8+ T cell expansion without suppressive regulatory T cells. Initial data showed NKTR-255 was well tolerated and biologically active, enhancing lymphocyte expansion.
Nektar Therapeutics (NASDAQ: NKTR) presented nonclinical data for its IL-15 pathway agonist, NKTR-255, at the 62nd ASH Annual Meeting. The research, in collaboration with Dana-Farber Cancer Center, highlights NKTR-255's potential to enhance natural killer (NK) cell and memory CD8 T cell functions. Currently in Phase 1b/2 studies, NKTR-255 aims to combine with agents like rituximab for treating multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL), showing promising anti-tumor activity.
Nektar Therapeutics (NKTR) announced notable data presentations regarding its immuno-oncology pipeline at the 2020 Society for Immunotherapy of Cancer Annual Meeting. Key developments include the PIVOT-02 study data for BEMPEG plus nivolumab, showing a 53% overall response rate and a 30.9-month median progression-free survival in Stage IV melanoma patients. NKTR also reported promising results for NKTR-262 and NKTR-255, with biological activity demonstrated in patients with hematologic malignancies. The findings underscore the potential of Nektar's therapies to effectively enhance anti-cancer immunity.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
